Munir Pirmohamed | Academic Influence

Munir Pirmohamed's AcademicInfluence.com Rankings

Munir Pirmohamed

Medical

#595

World Rank

#799

Historical Rank

Pharmacology

#45

World Rank

#62

Historical Rank

medical Degrees

Download Badge

Medical

Munir Pirmohamed's Degrees

Masters Medicine University of Liverpool
PhD Clinical Pharmacology University of Liverpool

Why Is Munir Pirmohamed Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Professor Sir Munir Pirmohamed is a British clinical pharmacologist and geneticist. Since 2007 he has been the NHS Chair of Pharmacogenetics at the University of Liverpool. Background He attended the former St Paul’s School and Peterborough Technical College.

(See a Problem?)

Munir Pirmohamed's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients (2004) (3053)
Drug repurposing: progress, challenges and recommendations (2018) (2048)
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin (2009) (956)
Phase I Clinical Trial of Oral Curcumin (2004) (819)
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. (2001) (815)
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. (2011) (675)
Active transport of imatinib into and out of cells: implications for drug resistance. (2004) (671)
Emergence and global spread of epidemic healthcare-associated Clostridium difficile (2012) (640)
Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes (2009) (630)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing (2011) (613)
Which drugs cause preventable admissions to hospital? A systematic review. (2007) (578)
A Randomized Trial of Genotype-Guided Dosing of Warfarin (2014) (440)
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. (2011) (421)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update (2017) (414)
The role of metabolic activation in drug-induced hepatotoxicity. (2005) (404)
Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance (2004) (394)
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology (2011) (380)
A randomized trial of genotype-guided dosing of warfarin. (2013) (365)
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. (2010) (341)
Adverse drug reactions (1998) (323)
Pharmacogenetics of warfarin: current status and future challenges (2007) (321)
Genetic susceptibility to adverse drug reactions. (2001) (319)
Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia (2008) (295)
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? (2011) (291)
ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research (2007) (287)
Warfarin: almost 60 years old and still causing problems. (2006) (276)
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. (2004) (275)
Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. (1998) (271)
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing (2012) (270)
Metabolism and bioactivation of clozapine by human liver in vitro. (1995) (255)
HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. (2006) (250)
Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing (2010) (223)
hOCT 1 and resistance to imatinib. (2005) (219)
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses (2011) (217)
Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. (2003) (212)
Clinical practice. Antibiotic allergy. (2006) (212)
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (2017) (208)
Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T Cells from Allergic Individuals1 (2000) (208)
Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (2012) (205)
Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. (2001) (203)
Management of allergy to penicillins and other beta‐lactams (2015) (202)
Human leukocyte antigen (HLA)‐B*57:01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury (2013) (198)
Review article: cellular and molecular mechanisms of NSAID‐induced peptic ulcers (2009) (195)
Characterization of drug-specific T cells in lamotrigine hypersensitivity. (2003) (191)
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing (2012) (183)
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (2018) (167)
Pragmatic randomised trials using routine electronic health records: putting them to the test (2012) (167)
The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. (2014) (161)
The danger hypothesis--potential role in idiosyncratic drug reactions. (2002) (160)
Phenotype Standardization for Statin-Induced Myotoxicity (2014) (157)
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. (2017) (157)
The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. (1995) (156)
Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool (2011) (156)
Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. (2002) (154)
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. (2009) (150)
Possible interaction between warfarin and cranberry juice (2003) (147)
Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis (2012) (146)
Characterisation of the toxic metabolite(s) of naphthalene. (1996) (144)
Cytochrome P450 enzyme polymorphisms and adverse drug reactions. (2003) (144)
Drug-grapefruit juice interactions (2013) (144)
Carbamazepine is not a substrate for P-glycoprotein. (2001) (141)
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. (2008) (141)
Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles (2014) (141)
Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. (1994) (140)
Immunological Principles of Adverse Drug Reactions (2000) (140)
Challenges and approaches for the development of safer immunomodulatory biologics (2013) (138)
Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. (1992) (135)
SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink (2013) (134)
Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. (2010) (133)
HLA Genotype and Carbamazepine‐Induced Cutaneous Adverse Drug Reactions: A Systematic Review (2012) (132)
TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients (2001) (131)
Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. (2002) (128)
Activation of T cells by carbamazepine and carbamazepine metabolites. (2006) (128)
Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism‐dependent haptenation and T‐cell proliferation in vivo (2001) (127)
Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. (2014) (126)
SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. (2018) (126)
Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity (1999) (126)
Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. (2001) (125)
Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. (2010) (122)
Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. (2000) (121)
Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature (2011) (120)
Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling1 (2007) (120)
Metabolic activation in drug allergies. (2001) (120)
The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. (1995) (118)
TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy (2002) (117)
Characterisation of flucloxacillin and 5‐hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo (2009) (116)
Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. (2000) (114)
Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. (2003) (113)
HIV and drug allergy (2001) (113)
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. (2011) (112)
Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. (1997) (112)
Pharmacogenetics and pharmacogenomics. (2001) (112)
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update (2014) (111)
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses (2011) (111)
Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. (2007) (109)
A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions (2016) (109)
Controversies in drug allergy: Testing for delayed reactions. (2019) (109)
Adverse drug reactions in hospitals: a narrative review. (2007) (108)
Social media and pharmacovigilance: A review of the opportunities and challenges. (2015) (107)
Phenotype Standardization for Immune‐Mediated Drug‐Induced Skin Injury (2011) (107)
Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components (2019) (106)
Effect of topiramate on acid-base balance: extent, mechanism and effects. (2009) (104)
Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters (2009) (104)
A method for the rapid depletion of albumin and immunoglobulin from human plasma (2004) (102)
Reporting of adverse drug reactions by nurses (2003) (102)
Pharmacovigilance in developing countries (2007) (100)
Mass Spectrometric Characterization of Circulating and Functional Antigens Derived from Piperacillin in Patients with Cystic Fibrosis (2011) (100)
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. (2008) (99)
Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population (2013) (98)
Zoonotic Transfer of Clostridium difficile Harboring Antimicrobial Resistance between Farm Animals and Humans (2017) (97)
Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital (2013) (97)
Genetic factors in the predisposition to drug-induced hypersensitivity reactions (2006) (96)
Metabolism of lamotrigine to a reactive arene oxide intermediate. (2000) (96)
Aminoglycoside-induced nephrotoxicity in children (2016) (94)
Aspirin resistance: effect of clinical, biochemical and genetic factors. (2011) (94)
The burden of alcohol misuse on an inner-city general hospital. (2000) (93)
Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene. (1996) (93)
Adverse drug reactions in hospital in‐patients: a pilot study (2006) (93)
Idiosyncratic Drug Reactions (1996) (91)
Mechanisms of Adverse Drug Reactions (2014) (90)
An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. (1992) (89)
Transport of gabapentin by LAT1 (SLC7A5). (2013) (88)
Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. (2000) (88)
Interaction of metoprolol and fluoxetine (1993) (88)
Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies (2017) (88)
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses (2020) (88)
Immunogenicity to Biologics: Mechanisms, Prediction and Reduction (2012) (87)
Hypersensitivity reactions to HIV therapy. (2011) (87)
An investigation of the formation of cytotoxic, genotoxic, protein-reactive and stable metabolites from naphthalene by human liver microsomes. (1993) (86)
Characterization of the Antigen Specificity of T-Cell Clones from Piperacillin-Hypersensitive Patients with Cystic Fibrosis (2012) (85)
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. (2012) (85)
Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. (2014) (85)
The Role of Active Metabolites in Drug Toxicity (1994) (85)
Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. (2001) (85)
Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. (1995) (84)
Pharmacogenetics: past, present and future. (2011) (84)
Direct Evidence for the Formation of Diastereoisomeric Benzylpenicilloyl Haptens from Benzylpenicillin and Benzylpenicillenic Acid in Patients (2011) (84)
Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children – a prospective observational cohort study of 6,601 admissions (2013) (83)
Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. (1991) (83)
Adverse Drug Reactions Causing Admission to a Paediatric Hospital (2012) (82)
Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. (1997) (82)
Characterization of amoxicillin‐ and clavulanic acid‐specific T cells in patients with amoxicillin‐clavulanate–induced liver injury (2015) (80)
Investigation of toxic metabolites during drug development. (2005) (80)
Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study (2006) (79)
Adverse drug reactions: back to the future. (2003) (79)
Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. (2005) (79)
Personalized medicine approaches in epilepsy (2015) (78)
New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity (2015) (77)
Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. (1998) (76)
Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs. (1998) (75)
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. (2019) (75)
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. (2019) (75)
A Proposal for an Individualized Pharmacogenetics‐Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy (2011) (75)
Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. (1995) (75)
Lamotrigine is a substrate for OCT1 in brain endothelial cells. (2012) (73)
Characterization of Sulfamethoxazole and Sulfamethoxazole Metabolite-Specific T-Cell Responses in Animals and Humans (2003) (73)
Polymorphisms in the TNF‐α and TNF‐receptor genes in patients with coronary artery disease (2001) (73)
Mechanism-Based Urinary Biomarkers to Identify the Potential for Aminoglycoside-Induced Nephrotoxicity in Premature Neonates: A Proof-of-Concept Study (2012) (73)
Pre-registration nurse education in pharmacology: is it adequate for the roles that nurses are expected to fulfil? (2002) (72)
Characterisation and Carriage Ratio of Clostridium difficile Strains Isolated from a Community-Dwelling Elderly Population in the United Kingdom (2011) (71)
Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy (2017) (71)
Mechanism of Clozapine-Induced Agranulocytosis (1997) (71)
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. (2013) (71)
Acceptance of Biomarker‐Based Tests for Application in Clinical Practice: Criteria and Obstacles (2010) (70)
Direct oral anticoagulants versus warfarin: is new always better than the old? (2018) (70)
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy (2011) (69)
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study (2009) (69)
The Phenotype Standardization Project: Improving Pharmacogenetic Studies of Serious Adverse Drug Reactions (2011) (69)
Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. (2017) (68)
Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK (2020) (68)
Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment. (2016) (67)
Oral anticoagulation: a critique of recent advances and controversies. (2015) (67)
In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers (2012) (67)
The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. (1997) (67)
Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol (2017) (67)
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. (2010) (67)
Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review (2015) (66)
Cost‐Effectiveness of Pharmacogenetics‐Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation (2014) (66)
Characterization of p-phenylenediamine-albumin binding sites and T-cell responses to hapten-modified protein. (2010) (66)
Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency (1996) (66)
A Review of the Important Role of CYP2D6 in Pharmacogenomics (2020) (65)
The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically‐diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010 (2012) (65)
Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence (2015) (64)
TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. (2002) (64)
The future prospects of pharmacogenetics in oral anticoagulation therapy. (2006) (64)
Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: Implications for immune mediated toxicity (1996) (63)
Reactive metabolites and their role in drug reactions (2001) (63)
Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource (2021) (62)
Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance (2006) (62)
Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta‐Analysis (2012) (62)
A role for the pregnane X receptor in flucloxacillin‐induced liver injury (2010) (61)
Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury (2015) (61)
Reported paediatric adverse drug reactions in the UK 2000-2009. (2012) (61)
Detection of Drug-Induced Acute Kidney Injury in Humans Using Urinary KIM-1, miR-21, -200c, and -423. (2016) (60)
General practice nurses' knowledge of alcohol use and misuse: a questionnaire survey. (2000) (60)
Cost‐effectiveness of screening for HLA‐A*31:01 prior to initiation of carbamazepine in epilepsy (2015) (60)
Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications of NMR and Mass Spectrometries (2010) (59)
Cardiovascular Pharmacogenomics: Expectations and Practical Benefits (2014) (59)
Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. (2000) (57)
Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. (2010) (57)
Pharmacovigilance of drug allergy and hypersensitivity using the ENDA–DAHD database and the GA2LEN platform. The Galenda project (2009) (57)
Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. (1991) (57)
Are chemically reactive metabolites responsible for adverse reactions to drugs? (2002) (57)
The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. (1992) (55)
Carbamazepine‐induced acute liver failure as part of the DRESS syndrome (2005) (55)
Assessment of Adipokine Expression and Mitochondrial Toxicity in HIV Patients With Lipoatrophy on Stavudine- and Zidovudine-Containing Regimens (2005) (54)
Parsing interindividual drug variability: an emerging role for systems pharmacology (2015) (54)
Predictive Genetic Testing for Drug‐Induced Liver Injury: Considerations of Clinical Utility (2012) (53)
The role of Clostridium difficile in the paediatric and neonatal gut — a narrative review (2016) (53)
Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster (2006) (53)
Hepatocellular response to chemical stress in CD‐1 mice: Induction of early genes and γ‐glutamylcysteine synthetase (2000) (53)
Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR (2019) (53)
HLA‐B*38:02:01 predicts carbimazole/methimazole‐induced agranulocytosis (2016) (52)
Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. (2014) (52)
Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study (2000) (52)
The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. (1999) (52)
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group (2014) (52)
Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. (1997) (52)
Altered Adipokine Response in Murine 3T3-F442A Adipocytes Treated with Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors (2005) (52)
Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis. (2014) (51)
Adverse drug reactions as cause of admission to hospital (2004) (50)
Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. (2003) (50)
Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy (2009) (50)
Genetics and the potential for predictive tests in adverse drug reactions. (2012) (50)
Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach (2007) (49)
Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study (2018) (49)
Intracellular Disposition and Metabolic Effects of Zidovudine, Stavudine and Four Protease Inhibitors in Cultured Adipocytes (2002) (49)
Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. (1996) (49)
Activation of T-cells from allergic patients and volunteers by p-phenylenediamine and Bandrowski's base. (2008) (48)
Pharmacogenomics: Current State-of-the-Art (2014) (48)
Genome‐wide association study of inhaled corticosteroid response in admixed children with asthma (2019) (48)
Monitoring drug treatment (2003) (47)
The role of polymorphisms of glutathione S-transferases GSTM1, M3, P1, T1 and A1 in susceptibility to alcoholic liver disease. (2004) (47)
The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. (2017) (47)
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (2012) (46)
Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. (1992) (46)
Immunopharmacology of hypersensitivity reactions to drugs (2003) (46)
Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors (2011) (46)
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia (2016) (46)
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. (2010) (45)
Safety assessment of peroxide antimalarials: clinical and chemical perspectives. (1998) (45)
Genomics of Adverse Drug Reactions. (2017) (45)
Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells. (2010) (45)
Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing (2019) (45)
Cost effectiveness analysis of HLA-B*58: 01 genotyping prior to initiation of allopurinol for gout (2017) (44)
Folate Augmentation of Treatment--Evaluation for Depression (FolATED): randomised trial and economic evaluation. (2014) (44)
Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles (2019) (44)
Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. (2006) (43)
Important questions in Allergy: 1 – drug allergy/hypersensitivity (2008) (43)
β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis. (2013) (43)
T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. (2013) (42)
Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality. (2015) (42)
A multi-factorial analysis of response to warfarin in a UK prospective cohort (2016) (42)
Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation (2015) (42)
Paediatric use of mycophenolate mofetil (2013) (41)
Genome-wide association study of serious blistering skin rash caused by drugs (2011) (41)
Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses? (2007) (41)
TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity (2017) (41)
Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011 (2014) (41)
Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review (2009) (40)
Shared Genetic Risk Factors Across Carbamazepine‐Induced Hypersensitivity Reactions (2019) (40)
Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. (1995) (40)
Pharmacogenetic tests: the need for a level playing field (2012) (40)
Tacrine-induced liver damage: an analysis of 19 candidate genes (2007) (40)
Pharmacogenetics of antiepileptic drug-induced hypersensitivity. (2014) (40)
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population (2017) (39)
Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery. (2011) (39)
Drug Induced Hypersensitivity and the HLA Complex (2010) (39)
Intravenous therapy (2004) (39)
Expanding Role of Pharmacogenomics in the Management of Cardiovascular Disorders (2013) (38)
Pharmacogenetics of idiosyncratic adverse drug reactions. (2010) (38)
Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. (2003) (38)
Identifying new antiepileptic drugs through genomics‐based drug repurposing (2017) (38)
Polymorphisms in the TNF-alpha and TNF-receptor genes in patients with coronary artery disease. (2001) (38)
The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. (2003) (37)
Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study (2014) (37)
A common missense variant of LILRB5 is associated with statin intolerance and myalgia (2017) (36)
Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. (2007) (36)
The Effect of Inhibitory Signals on the Priming of Drug Hapten–Specific T Cells That Express Distinct Vβ Receptors (2017) (36)
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? (2020) (36)
Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes (2008) (36)
Adaptation of host transmission cycle during Clostridium difficile speciation (2019) (36)
Early Deaths During Tuberculosis Treatment Are Associated With Depressed Innate Responses, Bacterial Infection, and Tuberculosis Progression (2011) (35)
A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy. (2014) (35)
Promiscuous T-cell responses to drugs and drug-haptens. (2015) (35)
HLA restriction of carbamazepine-specific T-Cell clones from an HLA-A*31:01-positive hypersensitive patient. (2014) (35)
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group (2017) (34)
Genetic Factors Influencing Warfarin Dose in Black‐African Patients: A Systematic Review and Meta‐Analysis (2019) (34)
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. (2010) (34)
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations (2014) (34)
Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study (2017) (33)
Pharmacogenetic Markers of Drug Efficacy and Toxicity (2015) (33)
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden (2016) (33)
Functional validity, role, and implications of heavy alcohol consumption genetic loci (2020) (33)
TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. (2009) (33)
The use of opioids and laxatives, and incidence of constipation, in patients requiring neck‐of‐femur (NOF) surgery: a pilot study (2008) (33)
What can we learn from parents about enhancing participation in pharmacovigilance? (2013) (33)
Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. (2016) (32)
The pharmacogenomics of HIV therapy (2001) (32)
Personalized medicine: decades away? (2006) (32)
Folate Augmentation of Treatment – Evaluation for Depression (FolATED): protocol of a randomised controlled trial (2007) (32)
The HLA-A*31:01 allele: influence on carbamazepine treatment (2017) (32)
Pharmacogenomics: the importance of accurate phenotypes. (2010) (32)
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients (2017) (32)
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. (2013) (32)
Measurement of CD4+ and CD8+ T-lymphocyte cytokine secretion and gene expression changes in p-phenylenediamine allergic patients and tolerant individuals. (2010) (31)
Causality Patterns for Detecting Adverse Drug Reactions From Social Media: Text Mining Approach (2018) (31)
Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink (2019) (31)
Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. (2017) (31)
Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. (2010) (31)
Thiopurine monitoring in children with inflammatory bowel disease: a systematic review (2014) (31)
Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff (2010) (30)
Warfarin dosing algorithms: A systematic review (2020) (30)
Pharmacogenomics in neurology: Current state and future steps (2011) (30)
The quality of information on monitoring for haematological adverse drug reactions. (2005) (30)
Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. (1997) (30)
Variability of antibiotic prescribing in patients with chronic obstructive pulmonary disease exacerbations: a cohort study (2013) (29)
Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities (2019) (29)
Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool (2015) (29)
SJS/TEN 2019: From science to translation. (2020) (29)
Adverse drug reactions causing admission to a paediatric hospital: a pilot study (2011) (29)
CYP2C19*17 Gain‐of‐Function Polymorphism Is Associated With Peptic Ulcer Disease (2013) (29)
Brief interventions in dependent drinkers: a comparative prospective analysis in two hospitals. (2011) (28)
Pharmacogenetics of Adverse Drug Reactions. (2018) (28)
Clinical Pharmacology (2004) (28)
Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity (2007) (28)
Toxicogenetics in drug development. (2001) (28)
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. (2015) (27)
The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. (2013) (27)
Pharmacogenetics of HIV therapy (2006) (27)
ADRIC: Adverse Drug Reactions In Children – a programme of research using mixed methods (2014) (27)
Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. (2015) (26)
Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi (2013) (26)
In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa. (2009) (26)
The recent emergence of a highly related virulent Clostridium difficile clade with unique characteristics (2020) (26)
Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. (2014) (26)
Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. (2018) (26)
A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp (2013) (26)
Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. (2015) (26)
Paediatric pharmacogenomics: an overview (2012) (25)
Biomarkers of adverse drug reactions (2018) (25)
New uses for old drugs (2018) (25)
Beyond registration--measuring the public-health potential of new treatments for malaria in Africa. (2006) (25)
Pharmacogenetics of warfarin in a paediatric population: Time in therapeutic range, initial and stable dosing, and adverse effects (2014) (25)
Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity (2021) (25)
Synthesis and Reactions of Nitroso Sulfamethoxazole with Biological Nucleophiles: Implications for Immune Mediated Toxicity. (1996) (25)
Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors (2020) (24)
Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. (1994) (24)
A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. (2019) (24)
Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia (2008) (24)
Genetic Association of Co‐Trimoxazole‐Induced Severe Cutaneous Adverse Reactions Is Phenotype‐Specific: HLA Class I Genotypes and Haplotypes (2020) (24)
Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. (2003) (23)
Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome (2017) (23)
An Investigation of Disagreement in Causality Assessment of Adverse Drug Reactions (2011) (23)
Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation (2013) (23)
Identification of Organ-Enriched Protein Biomarkers of Acute Liver Injury by Targeted Quantitative Proteomics of Blood in Acetaminophen- and Carbon-Tetrachloride-Treated Mouse Models and Acetaminophen Overdose Patients. (2016) (22)
Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study (2019) (22)
Enhancing Communication about Paediatric Medicines: Lessons from a Qualitative Study of Parents' Experiences of Their Child's Suspected Adverse Drug Reaction (2012) (22)
ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein (2013) (22)
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF☆ (2016) (22)
Defining drug response for stratified medicine. (2017) (22)
How do NHS general hospitals in England deal with patients with alcohol-related problems? A questionnaire survey. (2005) (21)
What are the social predictors of accident and emergency attendance in disadvantaged neighbourhoods? Results from a cross-sectional household health survey in the north west of England (2019) (21)
Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens (2020) (21)
Adverse drug reactions and pharmacogenomics: recent advances. (2008) (21)
17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use (2018) (21)
The adverse effects of drugs. (1999) (21)
Identifying cisplatin-induced kidney damage in paediatric oncology patients (2017) (21)
Warfarin: The End or the End of One Size Fits All Therapy? (2018) (21)
Characterization of the T-Cell Response in a Patient with Phenindione Hypersensitivity (2005) (21)
The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy. (2009) (21)
A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa (2020) (20)
Advances in the Pharmacogenomics of Adverse Drug Reactions (2015) (20)
Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression (2004) (20)
Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink (2014) (20)
HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis (2015) (20)
GATM gene variants and statin myopathy risk (2014) (20)
Bioactivation and bioinactivation of drugs and drug metabolites: Relevance to adverse drug reactions. (1994) (20)
The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy (2018) (20)
ST13 polymorphisms and their effect on exacerbations in steroid‐treated asthmatic children and young adults (2015) (20)
Genetics of epilepsy: epilepsy research foundation workshop report. (2007) (20)
Cost‐Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework (2019) (20)
Renal function monitoring in heart failure – what is the optimal frequency? A narrative review (2017) (19)
Through a Glass Darkly: Economics and Personalised Medicine (2014) (19)
Adverse drug reactions as cause of admission to hospital: Authors' reply (2004) (19)
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients (2021) (19)
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. (2012) (19)
No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease. (1998) (19)
Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. (2009) (19)
Towards better models and mechanistic biomarkers for drug‐induced gastrointestinal injury (2017) (19)
Immunological principles of T-cell-mediated adverse drug reactions in skin (2007) (19)
The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia (2014) (18)
Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients. (2017) (18)
The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities (2020) (18)
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals (2019) (18)
The association between polymorphisms in RLIP76 and drug response in epilepsy. (2007) (18)
Pharmacogenomics for Primary Care: An Overview (2020) (18)
Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. (2013) (18)
Idiosyncratic reactions to antidepressants: a review of the possible mechanisms and predisposing factors. (1992) (18)
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. (2021) (18)
COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records (2022) (17)
Specialist nurse reporting of adverse drug reactions. (2000) (17)
Lack association between schizophrenia and the CYP2D6 gene polymorphisms. (1996) (17)
An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. (2017) (17)
Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study (2020) (17)
Randomized Controlled Trial: Lisinopril Reduces Proteinuria, Ammonia, and Renal Polypeptide Tubular Catabolism in Patients With Chronic Allograft Nephropathy (2010) (17)
New Approaches to Investigate Drug-Induced Hypersensitivity. (2017) (17)
Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System (2014) (17)
Herbal medicines and acute medical emergency admissions to hospital. (2007) (16)
Validation of a multigenic model to predict seizure control in newly treated epilepsy (2014) (16)
Communication regarding adverse drug reactions between secondary and primary care: a postal questionnaire survey of general practitioners (1999) (16)
Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies (2017) (16)
Adrenal responses to a low‐dose short synacthen test in children with asthma (2011) (16)
Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. (2020) (16)
Development of ELISAs for diagnosis of acute typhoid fever in Nigerian children (2017) (16)
Patients Benefit From Genetics‐Guided Coumarin Anticoagulant Therapy (2014) (16)
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement (2019) (16)
Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin (2018) (16)
In Vitro Priming of Naı̈ve T-cells with p-Phenylenediamine and Bandrowski's Base. (2015) (16)
The role of polymorphism in manganese superoxide dismutase in susceptibility to alcoholic liver disease. (2003) (16)
LC determination of carbamazepine in murine brain. (2001) (16)
Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort (2020) (16)
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis (2016) (15)
The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. (2011) (15)
Collecting and sharing information about harms (2004) (15)
Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis (2016) (15)
Drugs and the retina. (2004) (15)
Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response (2017) (15)
Anticipating, investigating and managing the adverse effects of drugs. (2005) (15)
Precision Dosing in Children (2016) (15)
A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. (2017) (15)
Warfarin pharmacogenetics: economic considerations. (2007) (15)
Monocyte unresponsiveness and impaired IL1β, TNFα and IL7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis (2015) (14)
Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis (2015) (14)
Nurses' confidence in caring for patients with alcohol-related problems. (1997) (14)
Dual Glutathione‐S‐Transferase‐θ1 and ‐μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia (2014) (14)
Genetic regulation of gene expression in the epileptic human hippocampus (2017) (14)
High mobility group box 1 in the inflammatory pathogenesis of epilepsy: profiling circulating levels after experimental and clinical seizures (2014) (14)
Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity. (2018) (14)
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction (2020) (14)
Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study (2020) (14)
Research Directions in Genetic Predispositions to Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis (2018) (14)
Serum and blister‐fluid elevation and decreased epidermal content of high‐mobility group box 1 protein in drug‐induced Stevens–Johnson syndrome/toxic epidermal necrolysis† (2019) (14)
A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction (2014) (14)
Pharmacogenetics in reproductive and perinatal medicine. (2010) (14)
HLA-B*57:01-restricted activation of drug-specific T-cells provides the immunological basis for flucloxacillin-induced liver injury (2012) (13)
A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease (2016) (13)
Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives. (2013) (13)
Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. (2018) (13)
Genetic associations with clozapine-induced myocarditis in patients with schizophrenia (2020) (13)
Clinical review Fortnightly review Adverse drug reactions (1998) (13)
Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. (2000) (13)
Drug-Specific T Cells in An HIV-Positive Patient with Nevirapine-Induced Hepatitis (2005) (13)
Use of adrenal arterial embolization in severe ACTH-dependent Cushing's syndrome. (1989) (13)
Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention (2020) (13)
Pharmacogenomics in the UK National Health Service: opportunities and challenges. (2020) (13)
Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study (2019) (13)
Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis (2020) (13)
Serum Mannose-Binding Lectin Concentration, but Not Genotype, Is Associated With Clostridium difficile Infection Recurrence: A Prospective Cohort Study (2014) (13)
Pharmacogenetics in clinical practice: considerations for testing (2006) (13)
A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites (2020) (13)
Spontaneous Hemothorax Following Anticoagulation with Low-Molecular-Weight Heparin (2009) (13)
HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study (2017) (12)
Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response (2020) (12)
Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy (2015) (12)
Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort (2018) (12)
Epidemiology of alcohol dependence in UK primary care: Results from a large observational study using the Clinical Practice Research Datalink (2017) (12)
Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. (2015) (12)
Achieving the World Health Organization's vision for clinical pharmacology (2016) (12)
Kinetic parameters of lymphocyte microsomal epoxide hydrolase in carbamazepine hypersensitive patients. Assessment by radiometric HPLC. (1995) (12)
A population study of clinically actionable genetic variation affecting drug response from the Middle East (2022) (11)
Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts (2019) (11)
Reporting of adverse drug reactions: practice in the UK. (1998) (11)
Pharmacovigilance in developing countries : Requires collaboration between stakeholders to develop novel models of funding (2007) (11)
Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records. (2014) (11)
3 The pharmacology of the cytochrome P450 enzyme system (1998) (11)
Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis (2012) (11)
How important is aspirin adherence when evaluating effectiveness of low-dose aspirin? (2017) (11)
Clinical management of HIV-associated lipodystrophy (2009) (11)
Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease (2015) (11)
Immunomodulatory interventions for focal epilepsy syndromes. (2013) (11)
Repurposing Statins for Renal Protection: Is It a Class Effect? (2017) (11)
Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics (2015) (11)
Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study (2020) (10)
Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use (2020) (10)
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter (2021) (10)
Open letter on access to the BIA 10-2474 clinical trial data (2017) (10)
Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. (2020) (10)
Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor (2008) (10)
Pharmacotherapy for alcohol dependence: A stratified approach. (2015) (10)
Progress in pharmacogenetics: consortiums and new strategies (2016) (10)
The Implications of Pharmacogenetics and Pharmacogenomics for Drug Development and Health Care (2004) (10)
Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation (2020) (10)
Explanation for HLA-B*57:01-linked immune-mediated abacavir-induced hypersensitivity. (2012) (10)
The accumulation and metabolism of zidovudine in 3T3‐F442A pre‐adipocytes (2010) (10)
HLA DRB1*15:01-DQB1*06:02-restricted human CD4+ T-cells are selectively activated with amoxicillin-peptide adducts. (2020) (10)
TNF-α promoter region gene polymorphisms in patients with alcohol-induced chronic pancreatitis (2001) (10)
Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents. (2010) (10)
Adrenal responses to a low‐dose short synacthen test in children with asthma (2016) (10)
Genetic testing for prevention of severe drug-induced skin rash. (2013) (10)
Improving anticoagulation in sub‐Saharan Africa: What are the challenges and how can we overcome them? (2020) (9)
Randomised Evaluations of Accepted Choices in Treatment (REACT) trials: large-scale pragmatic trials within databases of routinely collected electronic healthcare records (2011) (9)
Genetic variants of hepatic transporters and susceptibility to drug induced liver injury (2008) (9)
Understanding drug interactions (2002) (9)
Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement☆ (2013) (9)
Characterization of Circulating Clostridium difficile Strains, Host Response and Intestinal Microbiome in Hospitalized Children With Diarrhea (2019) (9)
Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions (2022) (9)
Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf-α and Tnf-Receptor Levels, and on Metabolic Parameters (2004) (9)
Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries (2022) (9)
Safety perspectives on presently considered drugs for the treatment of COVID‐19 (2020) (9)
Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone (2015) (9)
Ethnic Diversity and Warfarin Pharmacogenomics (2022) (8)
Drug metabolism and drug toxicity (2001) (8)
High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study (2021) (8)
A pilot randomised controlled trial to assess the utility of an e‐learning package that trains users in adverse drug reaction causality (2015) (8)
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi (2010) (8)
A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC) (2011) (8)
The longitudinal NIHR ARC North West Coast Household Health Survey: exploring health inequalities in disadvantaged communities (2020) (8)
The adverse impact of COVID-19 pandemic on cardiovascular disease prevention and management in England, Scotland and Wales: A population-scale descriptive analysis of trends in medication data (2022) (8)
HLA‐DQ allele‐restricted activation of nitroso sulfamethoxazole‐specific CD4‐positive T lymphocytes from patients with cystic fibrosis (2015) (8)
Alcohol Abuse and the Burden on the NHS – Time for Action (2000) (8)
HLA Class II-restricted CD8+ T cells contribute to the promiscuous immune response in dapsone hypersensitive patients. (2021) (8)
Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma (2020) (8)
Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury. (2011) (8)
Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro (2018) (8)
Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01 (2021) (8)
Adipogenic gene variants in patients with HIV-associated lipodystrophy (2011) (7)
HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry (2021) (7)
Warfarin Pharmacogenetics (2012) (7)
TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy (2019) (7)
Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. (2017) (7)
The applications of pharmacogenetics to prescribing: what is currently practicable? (2009) (7)
Roadmap to 2030 for Drug Evaluation in Older Adults (2021) (7)
T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab (2021) (7)
Trends in BRCA testing and socioeconomic deprivation (2019) (7)
Genetic and nongenetic factors that may predispose individuals to allergic drug reactions (2018) (7)
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study (2023) (7)
P1112 : Baclofen: Maintenance of abstinence in alcohol dependent patients attending liver clinic (2015) (7)
Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters (2008) (7)
Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan (2006) (7)
Treatment of paracetamol overdose: room for improvement? (2014) (7)
HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds (2015) (7)
Is the interleukin 8 promoter polymorphism rs4073/-251T >A associated with Clostridium difficile infection? (2014) (7)
A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine (2014) (6)
Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. (2018) (6)
Deletion of exon 3 in the growth hormone receptor gene in adults with growth hormone deficiency: comparison of symptomatic and asymptomatic patients (2010) (6)
Erratum: Characterisation of the toxic metabolite(s) of naphthalene (Toxicology 114 (1996) (233)) PII S0300483X96035159 (1997) (6)
Emerging technologies and their impact on regulatory science (2021) (6)
Probenecid Increases the Concentration of 7-Chlorokynurenic Acid Derived from the Prodrug 4-Chlorokynurenine within the Prefrontal Cortex. (2020) (6)
T Cells from Allergic Individuals + Reactive Metabolites by Drug-Specific CD 4 Recognition of Sulfamethoxazole and Its (2000) (6)
The Interface of Therapeutics and Genomics in Cardiovascular Medicine (2021) (6)
Drug hypersensitivity reactions in patients with HIV disease (2007) (6)
Associations between occupation and heavy alcohol consumption in UK adults aged 40–69 years: a cross-sectional study using the UK Biobank (2021) (6)
Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 (2021) (6)
The clinical effectiveness and cost-effectiveness of testing for cytochrome P 450 polymorphisms in patients with schizophrenia treated with antipsychotics : a systematic review and economic evaluation (2009) (6)
Mechanisms of hypertransaminemia (1996) (6)
Hepatitis B vaccine and neurotoxicity. (1997) (6)
Susceptibility to drug induced liver injury determined by HLA class II genotype (2008) (6)
The 4C Initiative (Clinical Care for Cardiovascular disease in the COVID-19 pandemic): monitoring the indirect impact of the coronavirus pandemic on services for cardiovascular diseases in the UK (2020) (6)
Causality assessment of adverse drug reactions (2014) (6)
Anticoagulation in sub‐Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin (2020) (6)
Developing and Validating a Clinical Warfarin Dose‐Initiation Model for Black‐African Patients in South Africa and Uganda (2020) (6)
Similarity and consistency assessment of three major online drug–drug interaction resources (2021) (5)
The impact of the COVID-19 pandemic on cardiovascular disease prevention and management (2023) (5)
Multi‐ancestry genome‐wide association study of asthma exacerbations (2022) (5)
TEMPORARY REMOVAL: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. (2018) (5)
Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis. (1993) (5)
HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. (2021) (5)
Chapter 20 – Adverse Drug Reactions (2014) (5)
Risperidone-induced photosensitivity. (1998) (5)
Characterization of Clozapine-Responsive Human T Cells (2020) (5)
Factors Affecting Patient and Physician Engagement in Remote Health Care for Heart Failure: Systematic Review (2021) (5)
HLA- and immune-mediated adverse drug reactions: Another hit with vancomycin. (2019) (5)
The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. (2021) (5)
A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (2020) (5)
Commentary—bisphosphonates and calcium homoeostasis (2000) (5)
Haemolytic anaemia associated with indinavir (1999) (5)
Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury (2014) (4)
Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm (2021) (4)
Expression of the imatinib drug transporters hOCT1 and MDR1 levels determines imatinb response and development of BCR-ABL kinase mutations in chronic myeloid leukaemia (CML) (2005) (4)
Statins, immunomodulation, and infections: a complex and unresolved relationship. (2014) (4)
Risk modeling strategies for pharmacogenetic studies. (2011) (4)
An integrative in silico system for predicting dysregulated genes in the human epileptic focus: Application to SLC transporters (2016) (4)
A reference set of clinically relevant adverse drug-drug interactions (2022) (4)
RXR&ggr; gene variants are associated with HIV lipodystrophy (2013) (4)
Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine (2020) (4)
Lack of association between serious carbamazepine hypersensitivity reactions and HLA-B in Caucasians (2005) (4)
7th Drug hypersensitivity meeting: part two (2016) (4)
Alcohol related brain injury: an unrecognised problem in acute medicine. (2020) (4)
Pharmacogenomics: current status and future perspectives (2023) (4)
Quantification of urinary mevalonic acid as a biomarker of HMG-CoA reductase activity by a novel translational LC-MS/MS method. (2014) (4)
Chapter 5:Drug Transporters at the Blood–Brain Barrier (2016) (4)
Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype (2022) (4)
7th drug hypersensitivity meeting: part one (2016) (4)
Trimethoprim stimulates T-cells through metabolism-dependent and -independent pathways. (2011) (4)
Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells. (2007) (4)
Clinical coding of prospectively identified paediatric adverse drug reactions – a retrospective review of patient records (2014) (4)
Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of paediatric inpatients (2013) (4)
Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II) (2020) (4)
CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia (2017) (4)
Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial (2022) (3)
Changing Trends in Peptic Ulcer Disease: The Rise of NSAID-Induced and Fall of Helicobacter pylori-Induced Ulcers (2011) (3)
Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric (2013) (3)
Predicting the Safety of Medicines in Pregnancy: a Workshop Report. (2020) (3)
Unlike Imatinib, Dasatinib Uptake into Chronic Myeloid Leukaemia Cells Is Independent of hOCT1 Expression. (2007) (3)
The top 100 drug interactions. A Guide to Patient Management. 2003 Edition. (2004) (3)
Adverse drug reactions and off-label and unlicensed medicines in children : a nested case-control study of inpatients in a paediatric hospital (2013) (3)
Polymorphism in gene for microsomal epoxide hydrolase and lung disease (1997) (3)
66 Association of urinary kidney injury molecule-1 with aminoglycoside exposure in children with cystic fibrosis (2014) (3)
Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity (2021) (3)
Covalent adduction of carbamazepine 10, 11-epoxide with human serum albumin and glutathione S-transferase pi: implications for carbamazepine hypersensitivity (2014) (3)
S31 Variation at GLCCI1: Association with Increased Steroid Dose But Not Adrenal Suppression in Asthmatic Children (2012) (3)
Interleukin-10 promoter region polymorphisms and alcoholic liver disease (2001) (3)
Heart Failure in Practice. (2003) (3)
Identification of ROBO2 as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma (2021) (3)
CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (2017) (3)
Pharmacogenomics: Relevance and opportunities for clinical pharmacology (2022) (3)
An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol (2012) (3)
Drugs and the retina (2004) (3)
WARFARIN DOSING ALGORITHM REFINEMENTS AFTER 7-9 DAYS OF THERAPY BASED ON PHARMACOGENETIC, PHARMACOKINETIC, CLINICAL, AND LABORATORY DATA (2010) (3)
Stevens-johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines (2017) (3)
Genome-wide association study of inhaled corticosteroid response in African-admixed children with asthma (2017) (3)
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?: Report on the Medical Research Council Centre for Drug Safety Science workshop on 'Cardiovascular Toxicity of Medicines' (2011) (2)
Precision medicine in drug safety (2020) (2)
Pharmacodynamic and Pharmacokinetic Study of OralCurcuma Extract in Patients with Colorectal Cancer (2001) (2)
Discussion on Predictors of Response to Infliximab in Patients With Crohn's Disease (2002) (2)
Systematic review of paediatric adverse drug reactions (2014) (2)
Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK (2018) (2)
Vitamin D, vitamin D—binding protein, free vitamin D and COVID-19 mortality in hospitalized patients (2022) (2)
Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. (2019) (2)
HIV and Drug Hypersensitivity (2007) (2)
Learning Causality Patterns for Detecting Adverse Drug Reactions from Social Media (2018) (2)
TNF-α mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens-Johnson syndrome/ toxic epidermal necrolysis. (2022) (2)
resistance Active transport of imatinib into and out of cells: implications for drug (2013) (2)
An association study of common SNPs in SREBP‐2 and SCAP genes with simvastatin response in Saudi patients (2007) (2)
Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions (2014) (2)
SNP-Treatment Interactions of Cardiovascular Medications and Risk of Acute Coronary Syndrome Recurrence (2016) (2)
Response to “HLA Allelic Variants and Carbamazepine‐Induced Hypersensitivity” (2013) (2)
Managementof drug‐induced interstitial lung disease (2006) (2)
Urinary KIM-1 as a Biomarker of Aminoglycoside-Induced Nephrotoxicity in Premature Neonates (2011) (2)
Management of drug-induced interstitial lung disease (2006) (2)
Drug presentation to T cells. (2005) (2)
UK veterinary professionals’ perceptions and experiences of adverse drug reaction reporting (2022) (2)
Pharmacogenetics for the prescriber (2012) (2)
Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature (2011) (2)
Chapter 24 – Anticonvulsant Agents (2013) (2)
2. Pharmacogenetics of Adverse Drug Reactions (2012) (2)
Vitamin D, D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. (2022) (2)
A simple sore throat? (2000) (2)
Dexamethasone and Haemorrhage Risk in Paediatric Tonsillectomy: A Systematic Review and Meta-analysis (2015) (2)
Working together to deliver stratified medicine research effectively (2019) (2)
INTERACTION OF METROPOLOL AND FLUOXETINE (1993) (2)
Prescribing in liver disease (2002) (2)
Prescribing in epilepsy. (1990) (2)
' s response to reviews Title : Monocyte unresponsiveness and impaired IL 1 beta , TNFalpha and IL 7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis (2014) (2)
Optimal dose identification: predicting a safe dose in man from animal studies (2001) (1)
Point-of-care trials: the way forward– perspectives from patient representatives and general practitioner investigators (2014) (1)
Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration (2021) (1)
Combinations of medicines in patients with polypharmacy aged 65–100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions (2023) (1)
Identification of a PTPN22 missense variant as a general genetic risk factor for drug-induced liver injury (2018) (1)
Adrenal suppression with inhaled corticosteroids: the seed and the soil - Authors' reply. (2018) (1)
Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol (2022) (1)
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia (2016) (1)
Measurement of the urinary biomarker KIM-1 identifies the potential for aminoglycoside-induced nephrotoxicity in premature neonates (2011) (1)
Examining the uptake of predictive BRCA testing in the UK; findings and implications (2020) (1)
A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting. (2016) (1)
Su1780 CYP2C19*17 Gain of Function Mutation is Associated With the Development of Peptic Ulcer Disease (2012) (1)
The BPS web site for Continuing Professional Development in Clinical Pharmacology and Therapeutics (2003) (1)
Correction: Folate Augmentation of Treatment – Evaluation for Depression (FolATED): protocol of a randomised controlled trial (2009) (1)
Herbal medicines (2003) (1)
Pharmacogenomics: Relevance to personalized medicine (2017) (1)
DEVELOPMENT OF AN ADVERSE DRUG REACTION AVOIDABILITY ASSESSMENT TOOL (2014) (1)
Hydralazine-induced lupus: yet another autoantibody! (1996) (1)
Molecular medicine and genetics (2020) (1)
Polygenic risk scores: An overview from bench to bedside for personalised medicine (2022) (1)
Chapter 10 – Pharmacogenetics and Pharmacogenomics (2016) (1)
P272 Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way? (2020) (1)
Commentary: changing aetiology of peptic ulcers – author's reply (2012) (1)
Clinical coding of prospectively identified paediatric adverse drug reactions – a retrospective review of patient records (2014) (1)
Nucleic acid based therapies: developing frontier for precision medicine (2018) (1)
Characterization of amoxicillin and clavulanic-acid-responsive CD4+ And CD8+ T-cells in patients with co-amoxiclav-induced liver injury (2014) (1)
Best evidence and the clinical decision making process (2002) (1)
Characterisation of Sulfamethoxazole and Sulfamethoxazole Metabolite-Specific T-cell Responses in Animals and Man (2003) (1)
A multi-factorial analysis of response to warfarin in a UK prospective cohort (2016) (1)
Analysis of serum microRNA-122 in a randomised controlled trial of N-acetylcysteine for treatment of anti-tuberculosis drug-induced liver injury. (2023) (1)
Antigen exposure required for T cell activation (2014) (1)
The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities (2020) (1)
A reference set of clinically relevant adverse drug-drug interactions (2022) (1)
Metabolic Models of Cytotoxicity (1999) (1)
T‐cell‐mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis (2022) (1)
Genomics and therapeutics (2020) (1)
Development of the Liverpool Adverse Drug Reaction Avoidability Tool (2014) (1)
Correction: Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritization (2020) (1)
Socioeconomic and health factors related to polypharmacy and medication management: analysis of a Household Health Survey in North West Coast England (2022) (1)
PO-0926 Are Group Assessments Superior To Individual Avoidability Assessments? A Test Of The Liverpool Adverse Drug Reaction Avoidability Assessment Tool (2014) (1)
Value of information analysis for eLung (2014) (1)
Genome-wide association study of asthma exacerbations in European children treated with inhaled corticosteroids (2017) (1)
In silicoanalysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers (2012) (1)
STATIN-INDUCED MYTOTOXICITY (2017) (1)
Safety perspectives on presently considered drugs for the treatment of COVID-19 (2020) (1)
Chapter 8 – General pharmacology (2012) (1)
Personalized Medicine in Cardiovascular Disease (2017) (1)
Response 2 to pharmacogenetic screening to prevent carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome: a critical appraisal (2012) (1)
Genotype-guided dosing of vitamin K antagonists. (2014) (1)
Abs No: HLA-A*31:01 positive hypersensitive patient (2014) (1)
Genetic Predisposition to Anticonvulsant Hypersensitivity (2019) (1)
Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: the case of drug-drug interactions. (2023) (1)
SU102META-ANALYSIS OF CLOZAPINE-ASSOCIATED NEUTROPENIA AND AGRANULOCYTOSIS (2019) (1)
Characterization and Quantification of Mercapturate and Glutathione Conjugates of Nevirapine (2009) (1)
Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold? (2014) (1)
Meta-analysis of inhaled corticosteroids response in children with asthma (2019) (1)
Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation (2020) (1)
CME Clinical pharmacology (2005) (1)
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials (2022) (1)
Abstract 15111: Genome-Wide Association Study Links Variants With Occurrence of Cardiovascular Events in People Taking the COX-2 Inhibitor Celecoxib: Identification of NCKX2 as a Novel Protective Pathway in Renal Vessels (2017) (1)
Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. (2021) (1)
Changing trends in peptic ulcer disease: the rise of NSAID-induced and fall of H pylori-induced ulcers (2011) (1)
Tenofovir disoproxil fumarate and the kidney in HIV-infected patients: the evidence thus far. (2010) (1)
SU93 REPLICATION OF TWO INDEPENDENT LOCI IN HLA-DQB1 AND HLA-B CONTRIBUTING TO THE RISK OF CLOZAPINE-INDUCED AGRANULOCYTOSIS (2019) (1)
OWE-019 Mechanisms of chemotherapy-induced diarrhoea (2018) (1)
A PROSPECTIVE OPEN COHORT STUDY EXAMINING THE EFFECTIVENESS OF BACLOFEN IN AUD PATIENTS ATTENDING A JOINT LIVER AND ALCOHOL TREATMENT CLINIC (2016) (0)
A candidate gene study for oxaliplatin induced chronic peripheral neuropathy (OICPN) based on a prior genome wide association study (GWAS) (2016) (0)
Involvement of drug-specific CD4+ and CD8+ T-cells in trimethoprim-mediated hepatitis (2009) (0)
Pharmacogenetic origin of adverse drug reactions: A database study of CYP2C9 and CYP2D6-metabolised drugs (2005) (0)
Clinicians' attitudes to reporting adverse drug reactions (2000) (0)
Assessment of gene expression profiles of peripheral blood mononuclear cells from patients with a history of carbamazepine hypersensitivity (2017) (0)
A new frontier in atherosclerotic coronary imaging (2017) (0)
The characterisation of the loss of B cell memory to pneumococcal protein antigens in Malawian children during HIV infection (2009) (0)
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement (2019) (0)
A mechanistic investigation of the predisposing factors for idiosyncratic drug reactions. (1988) (0)
Pharmacogenomics of Anti-Cancer Drugs (2021) (0)
PP126—In-vitro reactivity of drug-specific t-cells from a HLA-A*31:01 positive carbamazepine hypersensitive patient (2013) (0)
Therapeutics 1995 (1995) (0)
Mandarin Translations (2011) (0)
Personalised medicine: Current opportunities and challenges (2020) (0)
Good Clinical Practice guidelines and point-of-care trials (2014) (0)
Cytochrome P450 genotyping: the UK perspective (2007) (0)
Characterization of Teicoplanin-Specific T-Cells from Drug Naïve Donors Expressing HLA-A*32:01 (2022) (0)
Characterization of Drug-Specific CD4+ T-Cells Reveals Possible Roles of HLA Class II in the Pathogenesis of Carbamazepine Hypersensitivity Reactions. (2023) (0)
The impact of P450 oxidoreductase knock out on systemic exposure to rosuvastatin, atorvastatin and atorvastatin metabolites (2017) (0)
from Piperacillin in Patients with Cystic Fibrosis Circulating and Functional Antigens Derived Mass Spectrometric Characterization of (2011) (0)
WHICH GENETIC PATHWAYS UNDERLIE PHARMACORESISTANT EPILEPSY? (2014) (0)
Independent members of Trial Steering Committee and Data Monitoring and Ethics Committee (2014) (0)
Developing a communication strategy about suspected adverse drug reactions affecting children (2014) (0)
p-Phenylenediamine-bound irreversibly to cysteine residues on human serum albumin activates T-cells from patients allergic to hair dye (2008) (0)
Genetic determinants of dose optimisation: molecular biology in the prevention of drug toxicity (2001) (0)
Drug presentation to T cells. Authors' reply (2005) (0)
Clinical Relevance of Drug–Drug Interactions With Antibiotics as Listed in a National Medication Formulary: Results From Two Large Population‐Based Case‐Control Studies in Patients Aged 65–100 Years Using Linked English Primary Care and Hospital Data (2022) (0)
Recruitment Strategy for Genetic Data Collection: The UK General Practice Research Database (2010) (0)
PAEDIATRIC ADVERSE DRUG REACTIONS (ADRS): A COMPARISON OF A NEWLY DEVELOPED AVOIDABILITY TOOL TO EXISTING HALLAS ASSESSMENTS (2016) (0)
Trends in BRCA testing and socioeconomic deprivation (2019) (0)
Follow-ups completed and imputed (2014) (0)
CYP2B6*18 is associated with nevirpine hypersensitivity independently of HLA-C*04:01 in a Malawian HIV population (2014) (0)
Elaborated clinical effectiveness results (2014) (0)
Author Correction: A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (2020) (0)
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective? (2003) (0)
Shared Clavulanate and Tazobactam Antigenic Determinants Activate T-Cells from Hypersensitive Patients (2022) (0)
Costimulatory Signaling Sulfamethoxazole Stimulate Dendritic Cell Sulfamethoxazole and Its Metabolite Nitroso (2007) (0)
Investigation of Tumour Necrosis Factor Receptor Polymorphisms in Alcoholic Liver Disease (1999) (0)
Clozapine elicits metabolism-mediated haptenation, glutathione depletion, apoptosis and necrosis within the neutrophil☆ (2000) (0)
Fibrosisfrom Piperacillin in Patients with Cystic Circulating and Functional Antigens Derived Mass Spectrometric Characterization of (2011) (0)
HLA-B*5701 and abacavir hypersensitivity - Reply. (2004) (0)
Defining uncontrolled childhood asthma in the global PiCA consortium (2016) (0)
Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients (2020) (0)
Early deaths during TB treatment are associated with depressed innate responses, bacterial infection and TB progression (2011) (0)
A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients (2022) (0)
Establishment of an HLA-typed cohort to elucidate the cellular and chemical basis of drug hypersensitivity reactions (2011) (0)
P13.01 Susceptibility of Clostridium difficile to single and combinations of antimicrobials (2010) (0)
Loss between referral and randomisation (2014) (0)
Elaborated demographic data (2014) (0)
Su1185 IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND PROGNOSIS: CAN UCEIS, MAYO AND NANCY INDEX SCORING POINT THE WAY? (2020) (0)
The need for patient-tailored dosing of baclofen in future clinical trials Response (2018) (0)
The unexpected challenges of immunotherapy (2018) (0)
Role of IL18 in HIV Associated Lipodystrophy (2008) (0)
PREDICTION OF IDIOSYNCRATIC DRUG REACTIONS (1993) (0)
Background, aims of project and exemplar trials (2014) (0)
The pharmacokinetic profile of Warfarn: a systematic review (2007) (0)
Plasma Methylmalonic Acid Concentration in Folic Acid–Supplemented Depressed Patients with Low or Marginal Vitamin B-12: A Randomized Trial (2021) (0)
Information technology system for flagging and data processing in point-of-care trials (2014) (0)
THE PROTEKT STUDY - A PHASE IIA, RANDOMISED, CONTROLLED, OPEN-LABEL TRIAL OF ROSUVASTATIN FOR THE PREVENTION OF AMINOGLYCOSIDE-INDUCED KIDNEY TOXICITY IN CHILDREN WITH CYSTIC FIBROSIS (2017) (0)
Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT (2019) (0)
Institutional profile: the Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK. (2013) (0)
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article end with the authors' clinical recommendations. Antibiotic Allergy (2006) (0)
Guidelines for CYP 2 C 9 and VKORC 1 Genotypes and Warfarin Dosing – ONLINE SUPPLEMENT (2011) (0)
Two distinct clinical trajectories of inflammatory thyroiditis evoked by checkpoint blockade in malignant melanoma. (2018) (0)
LETTERS Best evidence and the clinical decision making process (2002) (0)
Mechanistic biomarkers stratify patients after paracetamol overdose with high sensitivity and specificity (2017) (0)
SA82 HLA-DQB1 6672G>C INFLUENCES THE RISK OF CLOZAPINE-INDUCED AGRANULOCYTOSIS IN INDIVIDUALS OF EUROPEAN ANCESTRY (2019) (0)
Nalmefene in Supporting Alcohol Reduction: Observations from a Clinical (2015) (0)
Effect of Carbamazepine on TNF-α Expression: Comparison of Carbamazepine Hypersensitive and Non-Hypersensitive Patients (1999) (0)
Genome-wide association study of nevirapine hypersensitivity in a malawian HIV-infected population (2014) (0)
Novel OCT1 and OCT2 genetic variations—Potential link to metformin associated vitamin B12 deficiency during diabetes (2011) (0)
HLA-DQB1 6672 G>C is associated with the risk of clozapine-induced agranulocytosis in individuals of European ancestry (2020) (0)
PWE-165 CYP2C19*17 gain of function mutation is associated with peptic ulcer disease (2012) (0)
Establishment of an HLA-typed cohort of 1000 healthy blood donors and use of a dendritic cell priming assay to prime naive T cells to structurally divergent drugs (2014) (0)
th Meeting of the Irish Society of Human Genetics , Friday 2 nd (0)
Cost effectiveness of pharmacogenetic screening prior to initiation of carbamazepine treatment for epilepsy (2013) (0)
Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011 (2014) (0)
Recruitment into clinical trials (2014) (0)
A Double Blind Randomised Controlled Trial to Evaluate the Efficacy of Pre/Probiotic Enhanced Ready-To-Use Therapeutic Food (RUTF) in the Treatment of Severe Acute Childhood Malnutrition (0)
Implementation experiences with the exemplar trials (2014) (0)
121 Extended HLA analysis in a cohort of patients hypersensitive to beta-lactam antibiotics (2015) (0)
Nephrotoxicity in Children Receiving Chemotherapy - 'Omics and Biomarkers (2016) (0)
Glutathione Deficiency in Hiv-Infected Patients: A True or Technical Deficiency? (1996) (0)
Skewing of the TCR V repertoire in SMX-NO specific T cell responses (2014) (0)
TNF Receptor 1 Polymorphisms and the Risk of Coronary Artery Disease (CAD) (2000) (0)
Drug-specific lymphocyte proliferation in an HIV-positive patient with nevirapine hepatitis (2005) (0)
Examining the uptake of predictive BRCA testing in the UK; findings and implications (2020) (0)
IDENTIFYING AND CONFIRMING THE FUNCTIONAL VALIDITY OF GENETIC LOCI IN ALCOHOL CONSUMPTION USING UK BIOBANK (2019) (0)
Letter to the Editor: Response to Costa et al. (2018) (0)
Identification of a novel locus associated with asthma treatment response with inhaled corticosteroids in African-admixed children (2018) (0)
Paediatric Pharmacogenomics - Challenges and Opportunities. 2008; 2(1): 13-15 (2008) (0)
Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282]. (2022) (0)
Author’s reply to Backman and Bakhai (2013) (0)
Dates of initial approvals (2014) (0)
Proceedings of the Anaesthetic Research Society Meeting Royal College of Anaesthetists, London, UK, December 13–14, 2012 (2013) (0)
Checkpoint Inhibitor induced thyroid immune related adverse events: two distinct clinical patterns (2017) (0)
Research Implications from Adverse Drug Reactions In Children (2014) (0)
Preventing adverse drug reactions (2020) (0)
Effect of nucleoside reverse transcriptase inhibitors and protease inhibitors on TNF-alpha and adiponectin mRNA expression in isolated subcutaneous and omental mature human adipocytes (2005) (0)
Correction: The Effect of Inhibitory Signals on the Priming of Drug Hapten–Specific T Cells That Express Distinct Vβ Receptors (2018) (0)
EU-PACT Study: Initial Warfarin Dosing Improved by Clinical Variables and Genotype to Guide Therapy (2013) (0)
Liverpool Avoidability Assessment Tool glossary (2014) (0)
Corrigendum to 'SJS/TEN 2019: From science to translation' [J. Dermatol. Sci. 98/1 (2020) 2-12]. (2021) (0)
17q21 gene variation increases the risk of exacerbations in asthmatic children treated with inhaled corticosteroids: A meta-analysis in the multi-ethnic pica consortium (2017) (0)
Author Correction: A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (2020) (0)
Corrections (2008) (0)
Discussion, recommendations and guidance (2014) (0)
Trastuzumab Uptake In HER2-Positive Breast Cancer Patients: A Systematic Review And Meta-Analysis Of Observational Studies (2018) (0)
PM2 IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS (2009) (0)
Supporting data for general practitioner views and experiences of point-of-care trials (the Qualitative process Evaluation of ANtibiotics study results) (2014) (0)
Urinary Metabolite Signatures Are Associated With Low Cortisol Levels in Children Taking Inhaled Corticosteroids (2023) (0)
Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin (2018) (0)
Herbal medicines (2003) (0)
G-protein beta 3-subunit gene polymorphism and lymphocyte proliferation in carbamazepine hypersensitivity. (2005) (0)
Mode of uptake, accumulation and intracellular disposition of zidovudine in cultured 3T3-F442A preadipocytes (2003) (0)
Trial methodology used in this project (2014) (0)
Charters for Trial Steering and Data Monitoring Committees (2014) (0)
9 Applying personalised medicine in clinical practice (2018) (0)
Immunogenicity to Biologics: Mechanisms, Prediction and Reduction (2012) (0)
The Qualitative process Evaluation of ANtibiotics study: general practitioner andpatientinterview topic guides (2014) (0)
Faecal calprotectin levels in Clostridium difficile infection (CDI) cases versus Antibiotic-associated diarrhoea (AAD) controls. (2014) (0)
Statins: pharmacology, current uses and widening potential (2006) (0)
ADVISE: Adverse Drug Reactions in Children - International Surveillance and Evaluation - a multicentre cohort study (2012) (0)
Cost-effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions Plumpton, (2018) (0)
Childhood asthma exacerbations and the Arg 16 2-receptor polymorphism (2015) (0)
Phenotype Standardization for Statin-Induced (2014) (0)
Trial recruitment and data collection (2014) (0)
Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. (2023) (0)
Authors’ reply to Zermansky and Khatib (2011) (0)
Adaptation of host transmission cycle during Clostridium difficile speciation (2019) (0)
Management and prevention of drug‐induced major bleeding (2006) (0)
825 DEVELOPMENT OF THE ANTICHOLINERGIC MEDICATION INDEX (ACMI) (2022) (0)
EXAMINATION OF EQUITY IN THE DELIVERY OF PERSONALISED MEDICINES (2016) (0)
Drug Hypersnesitivity Meeting, Liverpool, 2006 (2006) (0)
HMGB1 expression in SJS/TEN sera and skin (2019) (0)
PCN254 - TRENDS IN BRCA TESTING OVER TIME AND SOCIOECONOMIC DEPRIVATION (2018) (0)
Scientific challenges in point-of-care trials (2014) (0)
P13.04 Exploring the clinical utility of faecal biomarkers to investigate Clostridium difficile infection (CDI) (2010) (0)
University of Dundee Association of Liver Injury From Specific Drugs , or Groups of Drugs , With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study (0)
Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients (2020) (0)
The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia (2013) (0)
Assessing the impact of alcohol consumption on the genetic contribution to mean corpuscular volume (2021) (0)
Mechanisms of Chemotherapy-Induced Diarrhoea (2017) (0)
Activation of human CD8+ T-cells with nitroso dapsone-modified HLA-B*13:01-binding peptides (2023) (0)
HLA-DQ restricted activation of nitroso-sulfamethoxazole-specific CD4+ T-lymphocytes (2014) (0)
Abstract 11847: Genotype-Guided Vitamin K Antagonist Dosing Algorithms Improve Time in Therapeutic Range: A Systematic Review and Meta-Analysis (2014) (0)
fludarabine plus cyclophosphamide in chronic lymphocytic leukemia is an independent determinant of inferior response to CYP2B6*6 (2014) (0)
Pharmacogenetics and Metabolic Disease (2016) (0)
S1.1 - Warfarin: A paradigm for individualized dosing (2020) (0)
Common clinical risk factors for drug-induced QT prolongation and torsades de pointes Female gender Conditions predisposing to heightened QT prolongation and risk of arrhythmia Heart disease Congestive heart failure Left ventricular hypertrophy Hours following conversion of atrial fibrillation to si (2013) (0)
A population study of clinically actionable genetic variation affecting drug response from the Middle East (2022) (0)
Textbook of Pharmacogenetics (2006) (0)
Drug allergy in lung disease (2010) (0)
Adverse drug reactions in children: reports to the UK yellow card scheme 2000–2009 (2011) (0)
PBI60 TRENDS AND UPTAKE OF PREDICTIVE BRCA TESTING (2019) (0)
PIN11 ABACAVIR HYPERSENSITIVITY: IS PREPRESCRIPTION GENOTYPING COSTEFFECTIVE? (2003) (0)
Chapter 37 Idiosyncratic drug reactions (1997) (0)
Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis (2015) (0)
Letter to the Editors medicines and acute medical emergency (2007) (0)
P45 The acceptability of using genetic information to guide treatment of asthma to children, young people, and parents (pilot study) (2019) (0)
chronic myeloid leukaemia Transporter 1 (hOCT1): implications for the treatment of imatinib resistant Effective dasatinib uptake may occur without human organic Cation (2013) (0)
Glutathione S-transferase theta 1 (GSTT1) gene copy number determines imatinib failure in chronic myeloid leukaemia (2014) (0)
PP122—Regulation of human leukocyte antigen expression and nevirapine-induced adverse drug reactions in a malawian hiv-positive population (2013) (0)
Cost-Effectiveness Of A Multi-Gene Panel In The Context Of Reducing Adverse Drug Reactions (2017) (0)
Title : Association of Liver Injury From Specific Drugs , or Groups of Drugs , With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study (2016) (0)
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement (2019) (0)
Summary of protocol changes approved by DMEC, TSC, MHRA, MREC and NCCHTA (2014) (0)
Tumour Necrosis Factor Alpha (TNFα) and TNF Receptor Polymorphisms and the Risk of Coronary Artery Disease (CAD) (2000) (0)
17q21 Gene Variance Increases The Risk Of Exacerbations In Asthmatic Children Treated With Inhaled Corticosteroids: A Meta-Analysis In The Pica Consortium (2017) (0)
Supplementary tables for single nucleotide polymorphisms (2014) (0)
Association of carboxyl-ester lipase variable nucleotide tandem repeat with alcoholic chronic pancreatitis and alcoholic liver disease (2014) (0)
Drug–Drug–Gene Interactions in Cardiovascular Medicine (2022) (0)
Inflammatory Bowel Disease: A Personalized Approach (2021) (0)
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group (2014) (0)
Letter: are idiopathic (non‐NSAID, non‐Helicobacter pylori) ulcers really increasing? Authors’ reply (2012) (0)
Symposium “Systems Medicine in Clinical Practice” (2019) (0)
The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy (2023) (0)
Clinical and Functional Evidence That Drug Transporter Expression Dictates the Response to Imatinib in Chronic Myeloid Leukaemia. (2006) (0)
Whole exome sequencing in individuals with statin-induced myopathy (2017) (0)
Pharmacogene variation in the UK 100,000 Genomes Project: an analysis of 60,221 individuals (2019) (0)
Specific HLA gene identified in vancomycin-induced DRESS (2019) (0)
Cancer pharmacogenomics (2020) (0)
O25 Genome wide analysis identifies potential mechanisms of non-alcoholic fatty liver disease (2022) (0)
Special Issue: Personalized Medicine [Guest Editors] (2010) (0)
Baclofen : Maintenance of Abstinence in Alcohol Dependent Patients Attending a Joint Liver and Alcohol Treatment Clinic (2015) (0)
Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis (2023) (0)
PO-0925 Children And Young People’s Experiences Of Adverse Drug Reactions And Pharmacovigilance In The Uk (2014) (0)
PTU-118 Baclofen As An Adjunct Pharmacotherapy For The Maintenance Of Abstinence In Alcohol Dependent Patients With Liver Disease (2014) (0)
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? (2020) (0)
Transcriptional response to glutathione depletion (2000) (0)
Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study (2023) (0)
Participant Information Leaflet and Informed Consent Form (2014) (0)
Multi-ancestral meta-analysis yields novel genetic loci for asthma exacerbations (2022) (0)
Cost-effectiveness analysis of antibiotics for chronic obstructive pulmonary disease exacerbations (2014) (0)
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement (2019) (0)
Session 10: Clinical pathology; dermatology; primary practice and the profession (2021) (0)
The immunogenicity of nitroso sulphamethoxazole in the rat: Metabolism-dependent T-cell reactivity (2000) (0)
Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia (2023) (0)
PHARMACOGENOMICS & PERSONALIZED THERAPY (2010) (0)
Systematic Review of Pharmacogenomics in Psoriasis (2013) (0)
Non-Medical Prescriber Experiences of Training and Competence to Report Adverse Drug Reactions (2017) (0)
Pharmacogenomics and antiviral drugs (2005) (0)
Qualitative process evaluation (QUalitative Evaluation of a trial of ANtibiotics for chronic lung disease study) (2014) (0)
Chronic Leg Pain (2020) (0)
G25 Communicating with parents following a suspected adverse drug reaction in a child: who says what and when? (2015) (0)
Effect of protease inhibitors on LDL receptor and IL-6 expression in lymphocytes and monocytes (2005) (0)
052 Exploring the genetic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery (2012) (0)
Adverse drug reactions : role of enzyme inhibition and induction (2009) (0)
ACTH-dependent Cushing's syndrome (2008) (0)
CSF: plasma HIV-1 RNA discordance > 0.5 log(10) is associated with raised inflammatory mediator profiles in CSF (2015) (0)
Corrigendum: Developing and Validating a Clinical Warfarin Dose‐Initiation Model for Black‐African Patients in South Africa and Uganda (2021) (0)
The role of Clostridium difficile in the paediatric and neonatal gut — a narrative review (2016) (0)
Families’ experiences of suspected adverse drug reactions: implications for communication and pharmacovigilance (2014) (0)
Health-Economic Evaluation of Clostridium Difficile Infection (Cdi) And Epidemiology In England And Merseyside. (2015) (0)
Immunogenicity to biologics: a central role for antigen processing and presentation (2012) (0)
A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (2020) (0)
Qualitative research of views on computerised trial recruitment for the information technology system design (2014) (0)

This paper list is powered by the following services:

Other Resources About Munir Pirmohamed

en.wikipedia.org

What Schools Are Affiliated With Munir Pirmohamed?

Munir Pirmohamed is affiliated with the following schools:

University of Liverpool